Clinical Trial Update: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update indicating pacritinib is being studied for relapsed/refractory T-cell lymphoproliferative disorders and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoproliferative Disorders

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: T-Cell Neoplasm, Lymphoproliferative Disorders | Phase 2 | Status: RECRUITING